Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Screening Trial for Never-Smokers
Dr West
Author
Howard (Jack) West, MD

One of the principles of screening is that the likelihood of detecting a cancer depends greatly on the risk that a person being screen has for developing that cancer. Low risk means that it is very likely that any abnormality that is detected is more likely to be unrelated to cancer. And because of that, nearly all of the screening efforts thus far have focused on patients with a significant smoking history.

But there are some patients who have a higher risk, even despite an absence of a smoking history. Among those would be considered at higher risk without a smoking history would be people with a significant family history of lung cancer (particularly an increased risk among people with a family history of lung cnacer in never-smokers, though the risk is still quite low), and people with a significant history of exposure to secondhand smoke. And now there's a study being done by a group that has a particular interest in the risk of lung cancer from secondhand smoke: flight attendants.

The Flight Attendants Medical Research Institute has sponsored a screening study for never-smokers (less than 100 cigarettes in a lifetime), a minimum age of 40 (cancer risk is age-related), significant exposore to secondhand smoke, no cancer history, and no prior CT in the preceding three years. The trial is currently being conducted at New York Presbyterian Hospital/Cornell's Weill Medical School in New York, Swedish Cancer Institute in Seattle, and some others. You can learn more about the trial here.

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on